NxStage Medical (NASDAQ:NXTM) will report earnings before markets open on Thursday, May 2nd. NxStage Medical, Inc. is medical device company that develops, manufactures, and markets systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. The Company’s primary product, the NxStage System One, is a small, portable hemodialysis system.
Here is your Cheat Sheet to Nxstage Medical Earnings:
Earnings Expectations: Analysts expect earnings of $-0.08 per share on revenues of $61.14 million.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.03 to a loss $0.07. For the current year, the average estimate is a loss of $0.24, which is worse than the estimate ninety days ago.
Here’s how Nxstage Medical has been performing on an annual basis:
|Revenue ($) in millions||128.76||148.68||179.22||217.26||242.13|
|Diluted EPS ($)||-1.23||-0.93||-0.66||-0.39||-0.26|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||57.02||56.95||59.01||61.15||65.02|
|Diluted EPS ($)||-0.0830||-0.09||-0.09||-0.04||-0.0400|
Nxstage Medical has beat analyst estimates 3 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.
“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)